Active	Status	Sponsor type	Region	Phase	Filter
13 Active 0 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

13 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
guo, Shiwei
ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.	Active, not recruiting	3	408	RoW	KN046, placebo	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Advanced Pancreatic Ductal Adenocarcinoma	04/24	08/24
ChanghaiH-PP09, NCT04931381: Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer	Recruiting	3	100	RoW	Chemotherapy guided by organoid drug sensitivity test	Changhai Hospital	Advanced Pancreatic Cancer	05/24	05/25
ChanghaiH-PP08, NCT04931394: Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer	Recruiting	3	200	RoW	Adjuvant chemotherapy guided by organoid drug sensitivity test	Changhai Hospital	Pancreatic Cancer	05/24	05/25
NCT04902261: Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer	Recruiting	2	140	RoW	Tislelizumab, Nab paclitaxel, Gemcitabine	Changhai Hospital	Recurrent Pancreatic Cancer	11/23	11/23
NCT06158516: A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors	Not yet recruiting	2	100	RoW	Surufatinib, Placebo	Changhai Hospital	Pancreatic Neuroendocrine Tumor	11/26	11/26
BRPCNCC-1, NCT03777462: Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1	Recruiting	2	150	RoW	Neoadjuvant gemcitabine plus nab-paclitaxel, Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT, Neoadjuvant S-1 plus nab-paclitaxel with SBRT	Changhai Hospital	Pancreatic Cancer	12/23	12/23
NCT06241352: Statin Addition to Chemotherapy for Advanced Pancreatic Cancer	Recruiting	2	40	RoW	statin addition to chemotherapy	Changhai Hospital	Advanced Pancreatic Cancer	12/24	02/27
ChanghaiH-PP05, NCT04324307: Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer	Recruiting	1/2	60	RoW	PD-L1/CTLA4 BsAb, GP, Gemcitabine, nab-Paclitaxel, FOLFIRINOX, Oxaliplatin, Irinotecan, Calcium Folate, Fluorouracil	Changhai Hospital	Locally Advanced and Metastatic Pancreatic Cancer	11/23	11/23
NCT04146298: Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer	Recruiting	1/2	30	RoW	Cyclophosphamide, Fludarabine, Mutant KRAS G12V-specific TCR transduced autologous T cells, Anti-PD-1 monoclonal antibody, Anti-PD-1	Changhai Hospital	Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma, Advanced Cancer	12/24	03/25
ChanghaiH-PP03, NCT03558945: Clinical Trial on Personalized Neoantigen Vaccine for Pancreatic Tumor	Recruiting	1	30	RoW	Personalized neoantigen vaccine	Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.	Pancreatic Tumor	11/23	12/23
PPDTPC, NCT04373928: Personalized Precision Diagnosis and Treatment of Pancreatic Cancer	Recruiting	N/A	100	RoW	Drug guided by Mini-PDX/PDX, Mini-PDX/PDX	Changhai Hospital	Pancreatic Cancer	12/24	12/24
NCT05495685: iDentification and vAlidation Model of Liquid biopsY Based cfDNA Methylation and pRotEin biomArKers for Pancreatic Cancer (DAYBREAK Study)	Recruiting	N/A	450	RoW		Changhai Hospital, Guangzhou Burning Rock Bioengineering Ltd	Cancer	12/23	06/24
Guo, Xiaodong
ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.	Active, not recruiting	3	408	RoW	KN046, placebo	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Advanced Pancreatic Ductal Adenocarcinoma	04/24	08/24